NCT01458197View on ClinicalTrials.gov

A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

PHASE2CompletedINTERVENTIONAL

Enrollment

235

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

November 30, 2012

Conditions

Overactive Bladder

Interventions

DRUG

Tarafenacin 0.2 mg

Capsule, qd, 12 weeks

DRUG

Placebo

Capsule, qd, 12 weeks

DRUG

Tarafenacin 0.4 mg

Capsule, qd, 12 weeks

Trial Locations (1)

138-736

Asan Medical Center, Seoul

All Listed Sponsors

lead

Kwang Dong Pharmaceutical co., ltd.

INDUSTRY

NCT01458197 - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. | Biotech Hunter | Biotech Hunter